CLS receives go-ahead from the US FDA for the latest version of TRANBERG Laser Fiber

Clinical Laserthermia Systems (CLS) (publ), which develops and markets Interstitial Laser Thermo Therapy (imILT), a polyclinical, heat-induced cancer immunotherapy for gentle and effective treatment , has received approval from the US Food and Drug Administration (FDA), via an 510(k) application, for the latest version of the TRANBERG Laser Fiber product, a radial fiber developed by the company for use in treatment with the imILT method.

CEO Lars-Erik Eriksson, CLS: "Following this positive decision from the FDA, we now have the latest version of the complete equipment ready and approved for the American market."

The approval is comparable to CE marking in the EU and means that the CLS product fulfills the comprehensive requirements that the FDA imposes on this type of medical device.

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ) develops and markets a safe, gentle, effective, and clinically documented therapy for treatment of solid cancer tumors. The product is based on immunostimulating interstitial laser thermotherapy (imILT). CLS is listed on Aktietorget under the stock symbol CLS B. More information is available on the Company's website www.clinicallaser.se